and 40 males; mean age 30 ± 16.8 years old) from Leprosy Clinic, Dr. Hasan Sadikin Hospital Bandung, Indonesia, were obtained through consecutive sampling.
Leprosy patients were grouped according to the clinical classification of Ridley and Jopling and consist of 1 TT, 16 borderline tuberculoid (BT), 8 mid-borderline (BB), 17 borderline lepromatous (BL), and 7 lepromatous leprosy (LL) patients. Blood sampling for anti-PGL-I IgM and IL-17A serum level assessment was performed in all subjects.
The study was approved by the Health Research Ethics Committee, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. Oral explanation about the study was made, and subsequently written informed consent was obtained from each participant.
Interleukin-17A expression
IL-17A expression in the skin was examined by immunohistochemistry method. Briefly, skin biopsy specimens were obtained through 5-mm punch biopsy from each patient. Immunohistochemistry analysis was done using IL-17A antibody (US Biological, Massachusetts MA, USA) with 1:100 dilution. Expression of IL-17A in the skin was quantified using an immunohistochemistry score (histoscore) ([intensity + 1] × distribution) and assessed by a certified pathologist.
Enzyme-linked immunosorbent assay

Anti-phenolic glycolipid-I immunoglobulin M level
Anti-PGL-I IgM level was examined using enzyme-linked immunosorbent assay (ELISA) method. [11] An ELISA plate was coated with 50 µl of natural trisaccharide-phenyl-bovine serum albumin (0.431 nmol of sugar/ml) and then, the surface of the wells was blocked by incubation with 1% bovine serum albumin (BSA) at 37°C for 60 min. Serum was diluted (1:300) with dilution buffer (phosphate-buffered saline with 20% fetal calf serum and 0.5% Tween 20) and added to the wells and incubated at 37°C for 60 min. After the plate was washed with washing buffer (phosphate-buffered saline with 0.05% Tween 20), peroxidase-conjugated antihuman IgG or IgM antiserum (Dako Igs A/S, Copenhagen, Denmark) was added to the wells and incubated at 37°C for 60 min. The excess of conjugates was removed with washing buffer, and then, a substrate solution (0.4 mg of o-phenylenediamine/ml and 0.4 µl of 30% hydrogen peroxide/ml in 0.1 M citrate-phosphate buffer, pH 5.0) was added, and the plates were developed in the dark for 15-30 min. The reaction was stopped by 1.25 M sulfuric acid. The levels of anti-PGL-I IgM in pg/ml were measured by an ELISA plate reader (Biolise, Vermont, USA).
Interleukin-17A levels in serum
Serum levels of IL-17A were measured by an ELISA using commercially available kits for IL-17A (R & D System, Minneapolis, USA) in accordance with the manufacturer's instructions.
Statistical analysis
Data were expressed as mean. The Rank-Spearman test was used for correlation analysis. P values < 0.05 were considered statistically significant results.
results
Interleukin-17A expression in leprosy patients
IL-17A expression quantification in the skin was performed. It was found that IL-17A was expressed in 46 of 49 patients' skin (93.87%). It was mainly expressed in the epidermis (93.87%), papillary dermis (91.83%), reticular dermis (46.93%), and periadnexal region (87.75%) [ Table 1 and Figure 1 ]. We also found IL-17A expression in keratinocytes and granulomas in the skin of leprosy patients [ Figure 2 ].
Comparison of IL-17A expression in the skin between clinical types of leprosy revealed statistically significant differences. In contrary, IL-17A serum levels between clinical types of leprosy showed insignificant differences [ Table 2 ].
The IL-17A expressions in skin biopsies of TT, BT, BB, BL, and LL type of leprosy using histoscore were 1.00, 2.31, 4.63, 5.06, and 10.14, respectively, and they showed significant differences (P = 0.0001).
Anti-phenolic glycolipid-I immunoglobulin M level
The titer of anti-PGL-I IgM levels was 89 pg/ml,; 555 pg/ml, 1.244 pg/ml, 1.920 pg/ml, and 23.591 pg/ml in TT, BT, BB, BL, and LL type of leprosy, respectively, and they showed significant differences (P = 0.005).
Correlation between interleukin-17A and anti-phenolic glycolipid-I immunoglobulin M
The correlation analysis results between IL-17A skin expression and anti-PGL-I IgM serum levels using RankSpearman test were as follows: r = 0.767 and P = 0.0001. This showed a very significant positive correlation [ Figure 3 ]. We suggested that the increase of IL-17A expression in the skin indicated the increase of anti-PGL-I IgM serum in leprosy.
dIscussIon IL-17A expression in the skin using immunohistochemical method in leprosy has never been reported before. To our knowledge, the present set of data provides the first evidence of IL-17A expression in the skin using immunohistochemistry method in leprosy patients.
Another analysis to examine IL-17A in leprosy has been described. Cirée et al. [6] showed the presence of IL-17A m-RNA through reverse transcriptase polymerase chain reaction method in LL skin, whereas no IL-17A mRNA could be detected in the TT leprosy skin lesions examined. da MottaPassos et al. [12] also demonstrated the presence of IL-17A mRNA in leprosy patients' skin that was found to be higher in lepromatous type than tuberculoid type. Those results of Cirée and da Motta-Passos studies were similar to this study, that the expression of IL-17A in the skin was significantly higher in lepromatous than tuberculoid type of leprosy [ Table 2 ]. The IL-17A was expressed in the epidermis, papillary dermis, reticular dermis, and periadnexal tissue [ Table 1 ].
Leprosy is manifested by a broad spectrum of clinical and immunology, ranging from TT leprosy to LL. Th1 cells are predominant in TT type, whereas the Th2 cytokine pattern is more prominent in lepromatous type. IL-17A is produced by Th17 [13] and also Th1, Th2, [14] or B cell. [9] In tuberculosis, IL-17A is inhibited by interferon-γ in vitro, [15] explaining the presence of higher IL-17A in lepromatous type than TT type of leprosy in our study.
Then, we compared the expression of IL-17A in the skin between types of leprosy using immunohistochemistry method. We found that IL-17A expression in the skin in each of clinical forms of leprosy showed significant differences. Therefore, IL-17A expression in the skin was higher in the lepromatous type compared with the TT type of leprosy. On the contrary, when we analyzed the IL-17A level in the serum between clinical forms of leprosy, it showed no significant differences [ Table 2 ]. Taken together, we suggest that IL-17A expression in the skin represented the type of leprosy.
We also found that there were statistically significant differences of anti-PGL-I IgM mean levels in various types Table 2 ]. Another group also mentions that anti-PGL-I IgM antibodies have been correlated to the total bacillary load of leprosy patients and have been reported to be adequate to monitor therapy, since antibody titer is decreasing with therapy.
[16] Furthermore, we reported for the first time that IL-17A expression in the skin showed a very significant positive correlation with the anti-PGL-I IgM serum levels in leprosy patients. The main source of IL-17A in this study could be B cells, but further researches are needed.
conclusIon
The increase of IL-17A expression in the lesional skin indicates the increase of anti-PGL-I IgM serum levels in leprosy. Hence, IL-17A could act as an adjunctive indicator of leprosy type and target of therapy in leprosy.
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